DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a single shot build a cancer army inside the body?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests an experimental gene therapy called UB-VV400, designed to instruct a person's own cells to become CAR T cells that target CD22 on B-cell cancers. It is given together with rapamycin, a drug that may help the therapy work better. The study enrolls adults with rela…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Umoja Biopharma • Aim: ⭐️ CURE ⭐️
Last updated Aug 01, 2026 00:00 UTC
-
Can a smart immune cell with a kill switch beat tough lymphomas?
⭐️ CURE ⭐️ Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
Ultra-Fast CAR-T cells aim to beat back tough lymphomas
⭐️ CURE ⭐️ Not yet recruitingThis phase 2 trial tests whether a new CAR-T cell therapy called UF-KURE19 can effectively treat adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The therapy is made from a patient's…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Kure Cells, INC • Aim: ⭐️ CURE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
Can a Two-Drug combo keep aggressive lymphoma at bay?
Disease control Not yet recruitingThis trial is testing whether a combination of pomalidomide (a pill) and rituximab (an infusion) can help young adults with high-risk diffuse large B-cell lymphoma (DLBCL) stay in remission after their first round of treatment. Participants, who must be under 60 and have responde…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a 'Universal' cancer target outsmart resistant blood cancers?
Disease control Not yet recruitingThis early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CA…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Vitruviae • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called birelentinib to standard chemotherapy (R-CHOP) improves outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Participants receive either birelentinib plus R-CHOP or a placebo plus R-CHOP. The s…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2, PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for lymphoma patients: glofitamab combo faces standard care in trial
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug glofitamab to standard chemotherapy (gemcitabine and oxaliplatin) works better than usual treatments for people with large B-cell lymphoma that has returned or not responded to first therapy. About 96 adults will be randomly …
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, glofitamab and selinexor, in 30 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. The goal is to see how many patients achieve a complete response (cancer dis…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a Macrophage-Targeting drug supercharge CAR-T therapy?
Disease control Not yet recruitingThis trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug targets Hard-to-Treat cancers with missing gene
Disease control Not yet recruitingThis early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for lymphoma: immune booster plus chemotherapy trial launches
Disease control Not yet recruitingThis Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a sid…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Mwanasha Merrill, MD • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Promising new combo targets tough lymphoma in older adults
Disease control Not yet recruitingThis study tests a new combination of drugs (mosunetuzumab and polatuzumab vedotin) plus chemotherapy for elderly patients (70 and older) with a newly diagnosed type of lymphoma called diffuse large B-cell lymphoma. The goal is to see if this approach helps more patients achieve …
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Colombia launches first CAR-T trial for Hard-to-Treat blood cancers
Disease control Not yet recruitingThis study aims to bring CAR-T cell therapy to Colombia for people with certain blood cancers that have come back or not responded to treatment. It has two parts: first, setting up the necessary partnerships and facilities to produce the therapy locally, and second, testing the s…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for lymphoma patients: experimental drug combo enters human trials
Disease control Not yet recruitingThis study tests whether adding the experimental drug lisatoclax to standard chemotherapy (R-CHOP or Pola-R-CHP) can safely improve outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 122 adults aged 18-70 will take part. The goal is to see if the comb…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental Dual-Targeting T-Cell therapy takes on tough lymphomas
Disease control Not yet recruitingThis early-phase trial will test a new type of immune cell therapy called bispecific AbTCR T-cells in 3 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, follicular, and Burkitt lymphoma). The cells are designed to target two proteins (CD19 and C…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 26, 2026 17:44 UTC
-
Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
Knowledge-focused Not yet recruitingThis study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study to track brain health after CAR-T cancer treatment
Knowledge-focused Not yet recruitingThis study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills before treatment and at 6, 12, and 24 months after. The goal is to learn how CAR-T therapy affects brain function …
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Real-World study to map next steps after key lymphoma drug fails
Knowledge-focused Not yet recruitingThis study looks at what happens to people with diffuse large B-cell lymphoma (a common blood cancer) after treatment with polatuzumab vedotin stops working. Researchers will track 200 patients in China to see which salvage treatments are used and how well they work. The goal is …
Matched conditions: DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC